La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Hofseth BioCare Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Hofseth BioCare.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	2.4%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Nov 20

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Hofseth BioCare non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

OB:HBC - Stime future degli analisti e dati finanziari passati (NOK Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2024	230	-121	-29	-19	N/A
3/31/2024	226	-98	-28	-17	N/A
12/31/2023	219	-107	-11	3	N/A
9/30/2023	205	-93	43	61	N/A
6/30/2023	185	-105	-6	11	N/A
3/31/2023	134	-140	-54	-36	N/A
12/31/2022	120	-137	-63	-45	N/A
9/30/2022	113	-136	-133	-114	N/A
6/30/2022	96	-139	-110	-90	N/A
3/31/2022	102	-135	-84	-53	N/A
12/31/2021	88	-126	-100	-62	N/A
9/30/2021	85	-120	-103	-59	N/A
6/30/2021	79	-115	-100	-43	N/A
3/31/2021	68	-111	-114	-56	N/A
12/31/2020	69	-102	-116	-62	N/A
9/30/2020	57	-104	-103	-54	N/A
6/30/2020	79	-90	-99	-63	N/A
3/31/2020	72	-86	-73	-49	N/A
12/31/2019	68	-89	-51	-31	N/A
9/30/2019	71	-79	19	25	N/A
6/30/2019	59	-81	-36	-36	N/A
3/31/2019	61	-83	-31	-23	N/A
12/31/2018	61	-85	-38	-29	N/A
9/30/2018	73	-74	-104	-81	N/A
6/30/2018	84	-66	-28	-3	N/A
3/31/2018	75	-66	N/A	-20	N/A
12/31/2017	66	-16	N/A	-25	N/A
9/30/2017	43	-28	N/A	-18	N/A
6/30/2017	19	-60	N/A	-43	N/A
3/31/2017	21	-92	N/A	-70	N/A
12/31/2016	20	-147	N/A	-67	N/A
9/30/2016	21	-165	N/A	-8	N/A
6/30/2016	34	-137	N/A	-2	N/A
3/31/2016	32	-109	N/A	1	N/A
12/31/2015	32	-100	N/A	8	N/A
9/30/2015	38	-84	N/A	-54	N/A
6/30/2015	23	-82	N/A	-47	N/A
3/31/2015	24	-72	N/A	-72	N/A
12/31/2014	20	-67	N/A	-61	N/A
9/30/2014	39	-40	N/A	-70	N/A
6/30/2014	62	-35	N/A	-103	N/A
3/31/2014	63	-39	N/A	-58	N/A
12/31/2013	63	-52	N/A	-77	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista HBC è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di HBC cresceranno più velocemente del mercato Norwegian

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di HBC cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di HBC cresceranno più rapidamente del mercato Norwegian.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di HBC cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di HBC è previsto essere elevato tra 3 anni

Hofseth BioCare Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Hofseth BioCare ASA Provides Earnings Guidance for the Second Half of 2021 and Next Year 2022

Recent updates

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.015 profit in 2Q 2023)

Less than half of directors are independent

First quarter 2024 earnings released: kr0.07 loss per share (vs kr0.096 loss in 1Q 2023)

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

New minor risk - Share price stability

Hofseth BioCare ASA Announces Board Changes

New major risk - Financial position

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

Hofseth BioCare ASA to Report Q4, 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.09 loss in 3Q 2022)

New minor risk - Market cap size

Second quarter 2023 earnings released: EPS: kr0.015 (vs kr0.079 loss in 2Q 2022)

CFO & COO recently bought kr200k worth of stock

New minor risk - Market cap size

Hofseth Biocare ASA Announces the Online Publication of Its Abstract

First quarter 2023 earnings released: kr0.10 loss per share (vs kr0.10 loss in 1Q 2022)

Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

Chief Scientific Officer recently bought kr538k worth of stock

Independent Director recently bought kr272k worth of stock

Full year 2022 earnings released: kr0.37 loss per share (vs kr0.35 loss in FY 2021)

We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Hofseth BioCare ASA to Report Fiscal Year 2022 Results on Mar 31, 2023

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Hofseth BioCare ASA's Progo Bioactive Peptides Now Is A "New Dietary Ingredient" for the US FDA

Second quarter 2022 earnings released: kr0.08 loss per share (vs kr0.069 loss in 2Q 2021)

Hofseth BioCare ASA Announces Executive Changes

Chief Executive Officer recently bought kr170k worth of stock

First quarter 2022 earnings released: kr0.10 loss per share (vs kr0.075 loss in 1Q 2021)

Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Full year 2021 earnings released: kr0.35 loss per share (vs kr0.31 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Chief Executive Officer recently bought kr367k worth of stock

Hofseth Biocare ASA Successfully Receive New Dietary Ingredient (NDI) Status from the US FDA

Third quarter 2021 earnings released: kr0.11 loss per share (vs kr0.10 loss in 3Q 2020)

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Chief Commercial Officer recently bought kr200k worth of stock

Chief Executive Officer recently bought kr361k worth of stock

Second quarter 2021 earnings released: kr0.07 loss per share (vs kr0.062 loss in 2Q 2020)

Hofseth BioCare ASA Provides Earnings Guidance for the Second Half of 2021 and Next Year 2022

Independent Director recently bought kr385k worth of stock

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.055 loss in 1Q 2020)

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

New 90-day high: kr9.80

Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 39.999995 million.

Hofseth Biocare ASA and Tenet Partners Initiate A Long-Term Collaboration to Build A Global Brand and Launch HBC Own Branded Consumer Health Products

Hofseth BioCare ASA and DKSH Announces A Pan-Asian Exclusive Collaboration for Distribution of HBC Branded Products Including Across China, India, Japan & Korea

Hofseth Biocare Asa Signs Exclusive Distribution Agreement with Leading Speciality Chemicals and Ingredients Distributor IMCD

Hofseth Biocare ASA Hires Andy Gill as VP from January 2021

Hofseth BioCare ASA, Annual General Meeting, Apr 23, 2021

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Hofseth Biocare ASA Approves Appointment of Christoph Baldegger as New Member of the Audit Committee

Third quarter earnings released

New 90-day low: kr7.98

HBC Receives Approval from Health Canada for Qualified Health Claims Focused on Maintaining Healthy Levels of Ferritin and Hemoglobin and the Blood Components Required for Oxygen Transport

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 200 million.

Hofseth Biocare ASA's Progo’s Bioactive Peptides to Support Healthy Iron Levels to Be Launched in the US

Hofseth BioCare ASA Announces the First Part of its Accelerated Phase 2 Trial of Cardio™ Soft Gels for the Treatment of Patients with COVID-19

New 90-day low - kr8.16

First half earnings released

Hofseth BioCare ASA (OB:HBC) acquired a 34% stake in Atlantic Delights Ltd. for $0.7 million.

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita